Cell-based Non-invasive Prenatal Test Workflow
ConditionPregnant Women
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorMenarini Silicon Biosystems
About this trial
The aim of this study is to optimize a new non-invasive prenatal screening method based on the capture of fetal cells from maternal blood and to complete its development by obtaining maternal blood samples during the first trimester of pregnancy.
Eligibility criteria
Qualifiers
Informed consent signed before any study-specific procedures
Pregnant women with singleton or twin pregnancy, at 8+0 - 14+6 week of gestation, aged ≥18 years
No medical contraindication for collecting 30 ml blood sample
Disqualifiers
Unable to provide informed consent
Known infections that carry a risk of vertical transmission
Known maternal viral diseases: HIV and HCV, HBV
Trial design
Treatments tested in this trial
- Blood collection
Treatment groups
1,400 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov